Recent 8-K filings for DXR
Highest-materiality recent filing
Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics
- No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.
- Deal expected to be immediately accretive and cash flow positive due to higher margins from in-house production.
-
Daxor raises ~$8.1M in registered direct offering of 765,958 shares at $11.75/share
Sold 765,958 shares at $11.75 per share for net proceeds of approx. $8,142,006 after fees.
-
Daxor files 8-K with investor presentation; no details available from provided text
Daxor Corporation issued a regulatory filing attaching an investor presentation on January 23, 2026.
-
Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer
FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.
-
Daxor reports annual meeting voting results; all director nominees elected, auditor ratified
All six director nominees elected; votes for ranged from 3,473,576 to 3,493,651.
-
Daxor holds annual meeting; re-elects six directors, ratifies auditor
All six director nominees elected with over 3.5M votes for each; no new directors.
-
Daxor resolves Nasdaq audit committee deficiency with appointment of Caleb DesRosiers
Nasdaq notified Daxor on May 30, 2024 of non-compliance with audit committee rule due to death of James A. Lombard.
-
Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics
No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.25 · Most common event other